Sildenafil distribution describes how the drug partitions between circulating plasma and tissues after entering systemic circulation. Current prescribing information reports a mean steady-state volume of distribution of approximately 105 L, indicating that sildenafil distributes beyond the vascular plasma compartment.
Plasma protein binding is another central distribution parameter. Sildenafil and its major circulating N-desmethyl metabolite are each approximately 96% protein bound, with labeling stating that the degree of binding is independent of total drug concentration.
This page explains what those sildenafil-specific findings mean and what they do not establish. Distribution is treated separately from chemical transformation on the sildenafil metabolism page and from removal efficiency on the sildenafil clearance page.
In pharmacokinetics, distribution is the reversible movement and partitioning of drug between the bloodstream and tissues after systemic entry. Once sildenafil has reached the circulation, the amount measured in plasma represents only the circulating portion of a larger dynamic drug pool.
Sildenafil labeling provides direct evidence that this distribution extends beyond plasma: the reported mean steady-state apparent distribution volume is approximately 105 L. That value is much larger than the physical plasma compartment and is interpreted pharmacokinetically as evidence of tissue distribution rather than as a literal anatomical space.
Within the broader sildenafil pharmacokinetic sequence, distribution begins after systemic entry but overlaps continuously with metabolism and clearance. It should therefore be viewed as a concurrent process rather than a discrete stage that completely ends before elimination begins.
| PK Stage | Primary Question |
|---|---|
| Absorption | How does sildenafil enter systemic circulation? |
| Distribution | How does sildenafil partition between plasma and tissues? |
| Metabolism | How is parent sildenafil chemically transformed? |
| Clearance / elimination | How is parent drug removed from the systemic drug pool? |
After sildenafil reaches systemic circulation, molecules can move between the central plasma compartment and tissues. This exchange is dynamic: drug can leave plasma, remain associated with tissue compartments for a period and subsequently redistribute as concentration gradients change.
The mean sildenafil Vss of approximately 105 L supports substantial distribution outside the circulating plasma space. It does not identify which individual tissues contain a particular concentration, nor does it mean sildenafil literally occupies 105 liters of anatomical fluid.
Labeling also provides a narrow example of measurement outside plasma: in healthy volunteers, less than 0.001% of an administered dose was measured in semen 90 minutes after dosing. That finding describes one sampled biological fluid and should not be generalized into a map of overall tissue distribution.
| Compartment or Observation | Distribution Interpretation |
|---|---|
| Plasma | Primary compartment used for routine PK concentration measurements. |
| Peripheral tissues | Contribute to the apparent distribution of sildenafil beyond plasma. |
| Mean Vss | Approximately 105 L, consistent with distribution into tissues. |
| Semen measurement | Less than 0.001% of administered dose measured 90 minutes after dosing in healthy volunteers. |
Current sildenafil labeling reports that approximately 96% of circulating sildenafil is bound to plasma proteins. Its major circulating N-desmethyl metabolite is also approximately 96% protein bound.
A 96% binding estimate corresponds conceptually to an unbound fraction of roughly 4% at a given equilibrium, but this should not be interpreted as meaning that only 4% of the administered sildenafil can ever reach tissues. Protein binding is reversible, so bound molecules can dissociate as unbound drug distributes or is eliminated.
Labeling also states that sildenafil protein binding is independent of total drug concentrations. In other words, the reported binding behavior was not described as becoming progressively saturated across the relevant observed concentration range.
| Distribution Parameter | Labeling Finding |
|---|---|
| Parent sildenafil protein binding | Approximately 96%. |
| N-desmethyl metabolite protein binding | Approximately 96%. |
| Approximate unbound fraction | About 4% at equilibrium, derived from the reported binding percentage. |
| Concentration dependence | Protein binding described as independent of total drug concentrations. |
Only unbound drug can directly participate in many immediate distribution and elimination processes, but the bound and unbound pools are not fixed populations. As unbound sildenafil leaves plasma, protein-bound drug can dissociate and restore the equilibrium.
This is why approximately 96% protein binding does not contradict a Vss of approximately 105 L. High plasma protein binding and substantial apparent tissue distribution can coexist because distribution reflects the complete equilibrium among plasma, proteins, tissues and ongoing drug removal rather than one static percentage.
Protein binding therefore cannot be used by itself to calculate tissue concentrations. Neither the 96% binding figure nor the 105 L Vss identifies how much sildenafil is present in a particular organ.
| Concept | What It Helps Describe | What It Does Not Establish |
|---|---|---|
| Approximately 96% protein binding | Balance between protein-associated and unbound sildenafil in plasma. | Exact concentration in a tissue. |
| Unbound fraction | Drug not protein-bound at that moment. | Total amount able to distribute over the entire dosing interval. |
| Vss ≈105 L | Overall apparent distribution behavior. | A literal 105-liter anatomical compartment. |
Apparent volume of distribution is a derived pharmacokinetic parameter relating the amount of drug associated with the body to its measured plasma concentration. Sildenafil prescribing information reports a mean steady-state distribution volume, or Vss, of approximately 105 L.
A distribution volume of this magnitude indicates that the amount of sildenafil present cannot be represented as though all drug remained confined to the plasma compartment. Relatively low plasma concentration compared with the total distributed amount produces a larger apparent volume.
The 105 L value is best used as a population-level pharmacokinetic reference. It should not be interpreted as the amount of body water containing sildenafil, the volume of blood exposed to the drug or a direct measurement of tissue penetration.
| Parameter | Sildenafil Context |
|---|---|
| Vss | Mean steady-state apparent volume of distribution. |
| Reported value | Approximately 105 L. |
| Primary interpretation | Sildenafil distributes beyond the plasma compartment into tissues. |
| Not a literal measurement of | Anatomical fluid volume or concentration in a specific organ. |
The word apparent is essential when interpreting sildenafil's approximately 105 L Vss. A pharmacokinetic distribution volume is calculated from relationships between drug amount and measured plasma concentration; it is not obtained by identifying a physical 105-liter compartment in the body.
When a drug partitions outside plasma, the circulating concentration can be low relative to the total amount associated with the body. The mathematical volume needed to describe that relationship can therefore exceed actual vascular or physiological fluid volumes.
For sildenafil, the label itself summarizes the practical interpretation of the 105 L value as indicating distribution into tissues. More detailed claims about individual tissue concentrations require direct tissue-specific evidence rather than extrapolation from Vss.
| Interpretation | Correct? |
|---|---|
| Sildenafil literally occupies 105 L of body fluid | No |
| Vss is a mathematical PK distribution parameter | Yes |
| The value supports distribution beyond plasma | Yes |
| Vss reveals the concentration in a specific tissue | No |
Plasma concentration can fall even when sildenafil has not yet been eliminated from the body, because some drug can move from the sampled vascular compartment into tissues. This redistribution is particularly relevant when interpreting the early post-peak concentration decline.
At the same time, sildenafil metabolism and systemic clearance are already occurring. A declining plasma concentration therefore represents the net result of distribution plus elimination rather than a direct measurement of either process in isolation.
The approximately 105 L Vss helps explain why plasma concentration alone should not be equated with the total amount of sildenafil present. The sildenafil concentration-time curve integrates these simultaneous processes across time.
| Observed Change | Possible Interpretation |
|---|---|
| Early plasma concentration decline | Distribution into tissues can contribute alongside elimination. |
| Continued post-peak decline | Metabolism and clearance increasingly shape the profile. |
| Low plasma concentration | Does not prove that all previously circulating drug has been eliminated. |
Distribution changes where sildenafil is located within the body, while elimination removes unchanged parent sildenafil from its systemic drug pool through metabolism and downstream removal processes. Moving from plasma into a tissue is therefore not itself elimination.
This distinction prevents a common interpretation error. If plasma concentration decreases because sildenafil redistributes into tissues, the amount measured in plasma falls even though the molecule can still remain within the body.
Conversely, metabolic transformation actually removes that molecule from the unchanged sildenafil pool. Elimination efficiency and its quantitative interpretation are covered separately on the sildenafil clearance page.
| Process | Direction | Primary Meaning |
|---|---|---|
| Distribution | Between plasma and tissue compartments | Reversible change in drug location. |
| Metabolic clearance | Out of the unchanged parent-drug pool | Chemical transformation contributes to parent-drug removal. |
| Excretion | Out of the body | Physical removal of drug-related material. |
Distribution and metabolism occur simultaneously but answer different pharmacokinetic questions. Distribution describes where unchanged sildenafil partitions, whereas metabolism describes conversion of parent sildenafil into new chemical species.
A sildenafil molecule can leave plasma and enter a tissue without being metabolized. Conversely, sildenafil reaching metabolically active compartments can undergo enzymatic transformation while distribution continues elsewhere in the system.
This distinction is particularly important because the major circulating N-desmethyl metabolite has its own distribution characteristics and is itself approximately 96% protein bound. The enzyme pathways generating that metabolite remain on the sildenafil metabolism page.
| Feature | Distribution | Metabolism |
|---|---|---|
| Primary question | Where does sildenafil partition? | How is sildenafil chemically transformed? |
| Changes chemical identity? | No | Yes |
| Can lower plasma parent-drug concentration? | Yes, through movement out of plasma | Yes, through transformation of parent drug |
| Major metabolite relevance | Metabolite is also approximately 96% protein bound | N-desmethyl sildenafil is produced through metabolism |
Distribution helps determine the relationship between the amount of sildenafil associated with the body and its plasma concentration, while clearance determines how efficiently parent drug is removed. Half-life emerges from the interaction of these disposition properties rather than from either one alone.
In simplified pharmacokinetic relationships, a larger distribution volume tends to lengthen the concentration-decline time scale when clearance is held constant, whereas greater clearance tends to shorten it when distribution is held constant.
Sildenafil labeling reports Vss of approximately 105 L and a terminal half-life of about 4 hours, but one value should not be used to infer the other without the appropriate clearance and model context. The time-based interpretation remains on the sildenafil half-life page.
| Parameter | Sildenafil Context |
|---|---|
| Vss | Approximately 105 L. |
| Clearance | Removal-efficiency component of sildenafil disposition. |
| Terminal half-life | About 4 hours in current labeling. |
| Relationship | Half-life reflects both distribution and clearance rather than distribution alone. |
Most sildenafil distribution information is inferred from plasma concentration data and derived pharmacokinetic parameters rather than from direct measurement in every tissue. The 105 L Vss is therefore a summary parameter describing overall disposition behavior.
Protein binding studies provide a separate piece of evidence: both parent sildenafil and its major circulating metabolite are approximately 96% bound, and labeling states that this binding is independent of total drug concentration.
Direct measurements in other biological matrices can answer narrower questions. The labeling observation that less than 0.001% of an administered sildenafil dose appeared in semen 90 minutes after dosing is one example, but it cannot be used to infer concentrations in unrelated tissues.
| Study Element | What It Can Tell Us |
|---|---|
| Serial plasma concentrations | How circulating sildenafil changes over time. |
| Vss | Overall apparent distribution behavior. |
| Protein-binding measurement | Fraction associated with plasma proteins under studied conditions. |
| Specific biological-fluid measurement | Concentration or recovered amount in that particular sampled matrix. |
| PK modeling | Conceptual relationships among central and peripheral compartments. |
Pharmacokinetic distribution is not expected to be perfectly identical in every individual, but sildenafil labeling provides stronger quantitative evidence for some distribution properties than for others. The best-established reference findings are Vss of approximately 105 L and approximately 96% plasma protein binding.
Importantly, protein binding is reported as independent of total drug concentration, so increasing total sildenafil concentration should not automatically be assumed to cause clinically meaningful saturation of plasma binding within the studied range.
Potential differences in plasma proteins, physiology or compartment behavior should not be used to explain an observed concentration difference without supporting data, because absorption and clearance can also change plasma concentrations. Broader between-subject variability belongs on the sildenafil PK variability page.
| Distribution Observation | Interpretive Limit |
|---|---|
| Vss ≈105 L | Population-level reference rather than an individual tissue map. |
| Protein binding ≈96% | Does not mean 96% of drug is permanently trapped in plasma. |
| Binding independent of total concentration | Does not support assuming concentration-dependent saturation from total sildenafil concentration alone. |
| Different plasma concentrations between people | Can also reflect absorption, metabolism or clearance rather than distribution. |
The sildenafil distribution data can be summarized by two complementary findings: a mean Vss of approximately 105 L indicates distribution beyond the vascular compartment, while approximately 96% plasma protein binding describes how most circulating parent sildenafil is reversibly associated with plasma proteins at a given time.
Those findings are not contradictory. Protein binding is dynamic, unbound drug can distribute, and bound drug can subsequently dissociate. Distribution, metabolism and clearance then continue simultaneously as the concentration-time profile evolves.
For the complete sequence from systemic entry through elimination, the sildenafil pharmacokinetics hub connects these distribution findings with absorption, exposure, metabolism, clearance and half-life.
| Research Question | Sildenafil-Specific Answer |
|---|---|
| Does sildenafil distribute beyond plasma? | Yes; mean Vss is approximately 105 L. |
| How strongly is sildenafil protein bound? | Approximately 96%. |
| Is the major metabolite also highly protein bound? | Yes; approximately 96%. |
| Does total sildenafil concentration change the reported binding percentage? | Labeling describes protein binding as independent of total drug concentrations. |
| Does Vss show the concentration in individual tissues? | No. |
Sildenafil distribution describes the reversible partitioning of the drug between plasma and tissues after systemic entry. Current labeling reports a mean steady-state apparent volume of distribution of approximately 105 L.
Current labeling reports that sildenafil is approximately 96% bound to plasma proteins. Its major circulating N-desmethyl metabolite is also approximately 96% protein bound.
No. The bound and unbound fractions exist in a reversible equilibrium. As unbound sildenafil distributes or is removed, bound drug can dissociate, so the binding percentage should not be interpreted as a permanent restriction of 96% of the dose to plasma.
The mean steady-state apparent volume of distribution reported in current sildenafil labeling is approximately 105 L, indicating distribution into tissues.
No. Vss is an apparent pharmacokinetic volume derived from the relationship between drug amount and plasma concentration; it is not a literal 105-liter body-fluid compartment.
Current labeling states that the plasma protein binding of sildenafil and its major circulating metabolite is independent of total drug concentrations.